HONG KONG, Feb. 6, 2026 /PRNewswire/ -- The BIEL Crystal Charity Trust has been officially established, marking a strategic upgrade in the company's philanthropic initiatives. By adopting a standardized, professional charitable trust framework, this move ushers in a new chapter for BIEL Crystal's public welfare efforts. The Trust will focus on key areas including education support, environmental protection, technological innovation, emergency disaster relief, and poverty alleviation.
About BIEL's Charitable Initiatives
Over the past two decades, BIEL Crystal has made cumulative donations exceeding USD 70 million worldwide. The newly established BIEL Charity Trust operates on a tripartite collaboration model involving the enterprise, a trust company, and a foundation, designed to ensure transparency in fund management, professional operation, and long-term sustainability in philanthropic endeavors.
Simon Yeung, Chairman of the BIEL Crystal Charity Trust, stated, "This marks a new beginning for BIEL Crystal's philanthropic journey of more than two decades and reflects our continued commitment to social responsibility." The Trust will collaborate with various sectors of society to ensure that every donation is utilized effectively, reaching and supporting more people in need.
About BIEL Crystal
BIEL Crystal is a leading global provider of exterior structure and module solutions for smart devices.Our products are widely used in smart digital devices, smart wearable devices, AR/VR glasses and automotive industry.Our long-term cooperation customers include Apple, Samsung, vivo, Meta, Tesla, Google and so on.
With more than 30 years of technological innovation and excellent management, BIEL Crystal has become a large technology innovation group with 9 advanced production bases worldwide, with a total investment of over HK$42 billion, covering a total area of about 4.3 million square meters, employing more than 100,000 people and with an annual production capacity of 2.2 billion pieces.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
BIEL Announces Establishment of BIEL Charity Trust
|
SEONGNAM, South Korea, Feb. 6, 2026 /PRNewswire/ -- PharmaResearch Co., Ltd. (CEO: Jihoon Sohn) today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for PRD-101, enabling the initiation of a Phase 1 clinical trial in the United States.
PRD-101 is a next-generation nano anticancer drug candidate formulated using nucleotide fragments produced through PharmaResearch's proprietary DOT® (DNA Optimizing Technology). The drug leverages the company's nucleotide-based Advanced DOT™ drug delivery platform, designed to enable efficient loading of therapeutics and improve pharmacokinetics.
The Phase 1 clinical trial will be conducted across up to seven clinical sites in the United States and is expected to enroll approximately 90 patients with locally advanced or metastatic solid tumors. The study is designed to evaluate the safety, tolerability, and pharmacokinetics of PRD-101.
"The FDA clearance of our IND application marks an important milestone for PRD-101. Through this Phase 1 trial, we aim to further characterize PRD-101 and continue advancing our oncology pipeline," PharmaResearch stated.
About PharmaResearch's PRD-101
PRD-101 represents a significant advancement in cancer treatment, utilizing nucleotide fragments produced through PharmaResearch's proprietary DNA optimizing technology (DOT®) in nanoparticle anticancer formulations. Collaborative efforts between PharmaResearch and the University of California Irvine (UCI) researchers, along with support from organizations like the U.S. NCL, have propelled the development of PRD-101. PharmaResearch holds patents and exclusive licenses associated with PRD-101, marking a milestone in the company's innovative endeavors.
Traditional anticancer drugs often face limitations due to high toxicity, which restricts patient eligibility and necessitates careful dosage management. PharmaResearch anticipates that PRD-101 will address these unmet medical needs in anticancer therapy.
About PharmaResearch
PharmaResearch is a pioneering biopharmaceutical company dedicated to enhancing the quality of life through regenerative medicine. With a diverse portfolio that includes medicines, medical devices, cosmetics, and supplements, PharmaResearch focuses on leveraging its core ingredients—DOT® PDRN and DOT ® PN—which are protected by a suite of patents. Headquartered in Gangneung-si, Gangwon-do, South Korea, PharmaResearch also has a subsidiary in Costa Mesa, California.
For more information about PharmaResearch, visit https://pharmaresearch.com/en
SEONGNAM, South Korea, Feb. 6, 2026 /PRNewswire/ -- PharmaResearch Co., Ltd. (CEO: Jihoon Sohn) today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for PRD-101, enabling the initiation of a Phase 1 clinical trial in the United States.
PRD-101 is a next-generation nano anticancer drug candidate formulated using nucleotide fragments produced through PharmaResearch's proprietary DOT® (DNA Optimizing Technology). The drug leverages the company's nucleotide-based Advanced DOT™ drug delivery platform, designed to enable efficient loading of therapeutics and improve pharmacokinetics.
The Phase 1 clinical trial will be conducted across up to seven clinical sites in the United States and is expected to enroll approximately 90 patients with locally advanced or metastatic solid tumors. The study is designed to evaluate the safety, tolerability, and pharmacokinetics of PRD-101.
"The FDA clearance of our IND application marks an important milestone for PRD-101. Through this Phase 1 trial, we aim to further characterize PRD-101 and continue advancing our oncology pipeline," PharmaResearch stated.
About PharmaResearch's PRD-101
PRD-101 represents a significant advancement in cancer treatment, utilizing nucleotide fragments produced through PharmaResearch's proprietary DNA optimizing technology (DOT®) in nanoparticle anticancer formulations. Collaborative efforts between PharmaResearch and the University of California Irvine (UCI) researchers, along with support from organizations like the U.S. NCL, have propelled the development of PRD-101. PharmaResearch holds patents and exclusive licenses associated with PRD-101, marking a milestone in the company's innovative endeavors.
Traditional anticancer drugs often face limitations due to high toxicity, which restricts patient eligibility and necessitates careful dosage management. PharmaResearch anticipates that PRD-101 will address these unmet medical needs in anticancer therapy.
About PharmaResearch
PharmaResearch is a pioneering biopharmaceutical company dedicated to enhancing the quality of life through regenerative medicine. With a diverse portfolio that includes medicines, medical devices, cosmetics, and supplements, PharmaResearch focuses on leveraging its core ingredients—DOT® PDRN and DOT ® PN—which are protected by a suite of patents. Headquartered in Gangneung-si, Gangwon-do, South Korea, PharmaResearch also has a subsidiary in Costa Mesa, California.
For more information about PharmaResearch, visit https://pharmaresearch.com/en
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
PharmaResearch Receives U.S. FDA Clearance to Initiate Phase 1 Clinical Trial of Nano Anticancer Drug, PRD-101
